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with the administration of active vitamin 
D metabolites. Reduced glomerular and 
tubulointerstitial alterations are accom-
panied by reduced proteinuria in experi-
mental diabetic nephropathy and other 
experimental kidney disease. Reduced 
proteinuria with administration of active 
vitamin D was also conﬁrmed in human 
subjects with chronic kidney disease. 
The reported increased susceptibility of 
the kidneys of VDR–/– mice to hypergly-
cemia might hold not only for diabetic 
nephropathy, but also for other chronic 
kidney diseases. These ﬁndings all sug-
gest that vitamin D deﬁciency should 
be avoided in diabetic and nondiabetic 
chronic kidney disease. However, the 
eﬀect of (low) doses of active vitamin D 
metabolites on development of diabetic 
nephropathy in patients with diabetes 
should be evaluated in prospective ran-
domized clinical trials.
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Preservation of residual renal 
function in peritoneal dialysis 
patients: Still a dream?
F Locatelli1 and V La Milia1
The results of the randomized trial by Fan et al. suggest that 
‘biocompatible’ peritoneal dialysis solutions have no major advantage 
over standard solutions in peritoneal dialysis patients in relation to 
residual renal function (RRF) and technique survival. The possible effect 
of more biocompatible peritoneal dialysis solutions on RRF should be 
tested in patients starting peritoneal dialysis programs with relatively 
well-preserved RRF. When RRF is already very poor, it is very unlikely that 
a more biocompatible peritoneal dialysis solution can preserve highly 
damaged and sclerotic kidneys. 
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Chronic kidney disease is often character-
ized by a progressive loss of renal function, 
and the start of dialysis further decreases 
residual renal function (RRF). This is of 
particular concern because RRF and diure-
sis are known to be major determinants of 
patient survival and, at least in the case of 
peritoneal dialysis, technique survival. It is 
therefore not surprising that nephrologists 
are interested in evidence-based data con-
cerning the best strategies for preserving 
renal function in patients on dialysis.
The results of observational studies 
have shown that high-ﬂux biocompatible 
membranes not only reduce serum β2-
microglobulin levels more eﬃciently than 
low-ﬂux bioincompatible membranes but 
also lead to a lower incidence of dialysis-
related amyloidosis and improve lipid 
profiles, peripheral nerve conductivity, 
and the susceptibility to infection.1 Even 
more important for the purposes of this 
Commentary is that the use of high-ﬂux 
biocompatible membranes had been asso-
ciated with a slower decrease in RRF in 
previously reported cohort studies.2
Cohort studies may have the advan-
tage of being more representative of all 
patients in real everyday clinical prac-
tice, but they are limited by the fact that 
controlling for confounding factors is 
restricted to what is already known and, 
although they can reveal associations, 
they can never prove causation. Further-
more, their positive ﬁndings are often 
contradicted by the surprising results of 
randomized controlled trials.
One clear example of this is the Hemo-
dialysis (HEMO) Study,3 which not only 
failed to conﬁrm previous observational 
data indicating that more dialysis is bet-
ter but, even more importantly, did not 
support the view that high-ﬂux biocompat-
ible dialysis is better than low-ﬂux dialysis. 
However, the preliminary results of the 
Membrane Permeability Outcome study4 
presented at the European Renal Asso-
ciation–European Dialysis and Transplant 
Association Congress in Barcelona in June 
seem to challenge the HEMO ﬁndings.
As preservation of RRF is associ-
ated with improved patient survival, 
any approach that may accomplish it is 
welcome not only in the early stages of 
chronic kidney disease (in an attempt to 
prevent the need for dialysis), but also in 
patients with stage 5 chronic kidney dis-
ease who are already on dialysis.
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In order to assess the impact of the bio-
compatibility of hemodialysis membranes 
on RRF, one prospective study randomly 
allocated 20 normotensive patients with 
tubulointerstitial nephritis to treatment 
with biocompatible high-ﬂux polysulfone 
or bioincompatible cellulose membranes 
for 12 months.2 RRF decreased in both 
groups after the start of hemodialysis, 
but the decrease was faster in the patients 
treated with cellulose membranes. Accord-
ing to the authors, the pathophysiological 
mechanism underlying the more rapid 
decline of RRF in patients treated with cel-
lulose membranes could not be explained 
by intradialytic hypotension but may 
be related to the nephrotoxic effects of 
inﬂammatory mediators due to membrane 
bioincompatibility. Unfortunately, the pre-
liminary results of the Membrane Perme-
ability Outcome study,4 which enrolled 
more than 700 patients, do not conﬁrm the 
positive results of this small trial.
As far as peritoneal dialysis is concerned, 
long-term changes in membrane structure 
(neoangiogenesis, advanced glycation 
end product formation, fibrosis, mes-
othelial denudation, and sub-mesothelial 
expansion) are responsible for functional 
alterations in peritoneal membranes, 
including increased small-solute transport 
and the loss of ultraﬁltration capacity, and 
can progress to encapsulating peritoneal 
sclerosis, a rare but life-threatening com-
plication of peritoneal dialysis.
The bioincompatibility of peritoneal 
dialysis ﬂuids (PDFs) is their low pH, the 
presence of lactate as buﬀer, hyperosmolal-
ity, and the presence of glucose and glucose 
degradation products (GDPs), which 
means that the requirements for more bio-
compatible PDFs are a physiological pH, a 
more balanced buﬀer system, little or no 
glucose, and reduced GDP production.
Multicompartmental bag systems 
increase pH, minimize the generation of 
GDPs during PDF heat sterilization, and 
introduce bicarbonate as a buffer. Fur-
thermore, multicompartmental solutions 
have proved to be superior to conventional 
PDFs during in vitro tests and in vivo tri-
als using surrogate end points such as the 
dialysate concentration of cancer antigen 
125 (CA125). These trials have shown 
increased CA125 concentrations in eﬄuent 
ﬂuid, and, although the clinical signiﬁcance 
of CA125 is not entirely clear, it is likely that 
CA125 levels reﬂect mesothelial-cell mass; 
so increased levels may be an index of a 
more preserved peritoneal mesothelium. 
Furthermore, a decrease in intraperitoneal 
hyaluronan levels may reﬂect reduced irri-
tation of the peritoneal membrane. Meas-
uring the dialysate levels of other markers 
(procollagen I peptides, transforming 
growth factor-β, vascular endothelial 
growth factor, tumor necrosis factor-α, and 
so on) did not lead to unequivocal results. 
Thus it has been suggested that the use of 
biocompatible solutions is associated with 
a more preserved peritoneal membrane.
The use of more biocompatible dialy-
sis solutions in clinical practice has been 
associated, in a retrospective study, with 
better survival, albeit without any asso-
ciation with peritoneal technique sur-
vival or the rate of peritonitis.5 These 
results have been interpreted as being 
possibly due to the better preservation 
of RRF in the patients treated with more 
biocompatible solutions,5 and this is 
supported by the ﬁndings of the Euro- 
Balance Trial,6 although this also has 
some methodological drawbacks.
We find it difficult to believe that 
using a more biocompatible peritoneal 
dialysis solution (or more biocompatible 
Table 1 | Dialysate markers and clinical findings in the major clinical trials performed with new multicompartmental 
peritoneal dialysis fluids (PDF)
PDF Clinical design Pts M Dialysate markers IP MP UF RRF P References
Physioneal
(Baxter)
CAPD; prospective,  
randomized, parallel
CAPD; randomized,  
double-blind, crossover
CAPD; prospective,  
randomized, parallel
APD; prospective,  
randomized, crossover
CAPD and APD; prospective, 
randomized, parallel
46 
17 acute 
106 
14 
118
2 
 
6
 
12
 
12
 
  
↑CA125, ↓HA
 
↑CA25
 
↓ 
↓
 
↓
= 
 
= 
 
=
= 
 
↑ 
 
=
=
 
 
 
 
=
=
 
 
 
= 
 
=
Coles et al., 19988
 
Mactier et al., 19989
 
Tranaeus, 200010 and 
Jones et al., 200111
Fusshoeller et al., 200412 
 
Fan et al., 20087
Gambrosol trio
(Gambro)
CAPD; prospective,  
randomized, parallel
CAPD; prospective,  
randomized, crossover
80 
21
24 
4
↑CA125, ↓HA 
↑CA125
= = = = = Rippe et al., 200113
 
Zeier et al., 200314
Balance
(Fresenius Medical 
Care)
CAPD; prospective, randomized, 
crossover with parallel arms; 
CAPD; prospective,  
randomized, parallel
86 
50
6 
12
↑CA125, ↓HA 
↑CA125, ↓HA
↑ ↓ 
=
↑ 
=
 
=
Williams et al., 20046
 
Szeto et al., 200715
BicaVera
(Fresenius Medical 
Care)
CAPD; prospective, randomized, 
crossover
APD; prospective, randomized, 
crossover
69 
28 pediatric
6 
6
 
↑CA125
= 
↓
= 
=
= 
=
= 
=
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Pts, patients; M, months; IP, infusion pain; MP, membrane permeability; UF, ultrafiltration; RRF, residual renal function; P, peritonitis; CAPD, continuous ambulatory peritoneal 
dialysis; APD, automated peritoneal dialysis; CA125, cancer antigen 125; HA, hyaluronic acid.
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membranes) for a relatively short period 
of time can independently affect the 
RRF of dialysis patients significantly, 
because of the many confounding vari-
ables involved, including the correct 
estimation of the patients’ dry body 
weight, which, in our opinion, is prob-
ably the most important factor aﬀecting 
the preservation of RRF and diuresis. In 
the Euro-Balance Trial,6 hypervolemia 
may have contributed to preserving 
RRF in the patients randomized to the 
biocompatible solutions. Furthermore, it 
is necessary to consider the use of drugs, 
including angiotensin-converting enzyme 
inhibitors and angiotensin II receptor 
blockers, that may greatly aﬀect RRF by 
improving or worsening renal function; 
in addition, it is always diﬃcult to ensure 
the balanced distribution of these drugs 
among the patients randomized to dif-
ferent treatments in controlled trials, as 
well as the delicate question of patients’ 
compliance with their prescription, 
which can be a major confounding factor. 
Other important factors possibly aﬀect-
ing RRF are infections (including perito-
nitis in peritoneal dialysis patients) and 
the potentially nephrotoxic antibiotics 
needed to treat them.
Fan et al.7 (this issue) now describe a 
well-planned prospective (albeit open-
label) study designed to analyze the 
potential benefit of neutral-pH, low-
GDP ‘biocompatible’ peritoneal dialysis 
solutions in relation to RRF. The results 
strongly suggest that such solutions do not 
have any major advantage over standard 
solutions in patients on continuous ambu-
latory or automated peritoneal dialysis. 
The study also analyzed the eﬀect of these 
solutions on membrane function and 
technique survival, once again ﬁnding no 
signiﬁcant diﬀerences.
The authors themselves acknowledge 
that the study was underpowered to exam-
ine the impact on peritonitis and tech-
nique survival,7 but, given the very few 
prospective randomized trials in this ﬁeld 
(Table 1), we ﬁnd it interesting even with 
these limitations. The previously reported 
associations between improved survival 
and biocompatible solutions, suggesting 
that preserved RRF could be a possible 
explanation, were derived from retrospec-
tive analyses or small trials, rather than a 
randomized, adequately sized, controlled 
trial designed for this purpose.
In line with the well-known view of 
‘the earlier the prevention, the better,’ it 
has been clearly demonstrated that earlier 
interventions are much more successful in 
preserving renal function in patients with 
early-stage chronic kidney disease. The 
possible eﬀect of more biocompatible perit-
oneal dialysis solutions on RRF should 
therefore be further tested in patients 
starting peritoneal dialysis programs with 
relatively well-preserved RRF. When RRF 
is already very poor, it is very diﬃcult to 
believe that a more biocompatible perito-
neal dialysis solution can preserve highly 
damaged and sclerotic kidneys, and we 
strongly believe that hemodynamic factors 
may be much more important, including 
correctly evaluating patient dry body 
weight, balancing the risk of overhydra-
tion with the risk of jeopardizing RRF, and 
avoiding potentially nephrotoxic drugs 
and carefully using those that are poten-
tially nephroprotective.
However, we do agree that using a 
more biocompatible peritoneal dialysis 
solution may reduce the rate of infections 
(peritonitis) and thus reduce the risks 
associated with the potentially nephro-
toxic antibiotics used to treat them, and 
we cannot rule out the possibility that 
this may help to preserve RRF.
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